ArticleJournal of animal science2025
Effects of Bacillus subtilis ATCC PTA-122264 on apparent total tract macronutrient digestibility and fecal characteristics, metabolites, and microbiota of healthy adult dogs.
Article in Journal of animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical and Faecal Outcomes in Adult Dogs with Chronic Enteropathy Fed an Hydrolysed Protein Diet with and WithoutAnimals : an open access journal from MDPI · 2026Article
- Dietary Supplementation withAnimals : an open access journal from MDPI · 2025Article
- Probiotics in Pet Food: A Decade of Research, Patents, and Market Trends.Foods (Basel, Switzerland) · 2025Review
- Evaluation ofFrontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal and stool quality issues are common in companion animals. In addition to dietary fibers and prebiotics, the consumption of live microorganisms may be used to support the gastrointestinal health of pets. Spore-forming Bacillus species are gaining interest due to their viability during processing, storage, and within the gastrointestinal tract. The objective of the current study was to determine the effects of B. subtilis ATCC PTA-122264 supplementation on dietary apparent total tract macronutrient digestibility and the fecal characteristics, metabolites, and microbiota of healthy adult dogs. Twelve healthy adult beagle dogs (6 ± 1.14 yr; 8.71 ± 0.91 kg body weight) were used in a replicated 3 × 3 Latin square design. Dogs were fed to maintain body weight and allotted to 1 of the 3 treatments each experimental period (n = 12/treatment): Control [kibble diet + placebo (1.25 g of maltodextrin)], Low [kibble diet + 1 × 109 colony-forming units (CFU)/d of B. subtilis], and High (kibble diet + 5 × 109 CFU/d of B. subtilis). Each experimental period was composed of a 22-d adaptation phase, 5-d fecal collection phase, and 1 d for blood collection. Fecal microbiota data were evaluated using QIIME2. All other data were analyzed using the Mixed Models procedure of SAS, with P < 0.05 being considered significant. B. subtilis supplementation tended to decrease (P < 0.10) apparent total tract dry matter, organic matter, and energy digestibilities but did not influence food or energy intake, fecal output, and apparent total tract protein or fat digestibilities. Most serum metabolites, hematology, fecal characteristics, and fecal bacterial alpha and beta diversity indices were not affected. Fecal dysbiosis index tended to be affected and fecal Streptococcus, Escherichia coli, and Blautia abundances were lower (P < 0.05) in dogs allotted to the Low treatment. These data suggest that daily supplementation of up to 5 × 109 CFU/d of B. subtilis ATCC PTA-122264 is safe and does not affect markers of general health and fecal characteristics of healthy dogs, warranting further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.